Oligonucleotide CDMO and CRDMO Services Market Overview
Oligonucleotide CDMO and CRDMO Services market was valued at USD 1.4 billion in 2024 and is projected to grow to USD 2.62 billion by 2031, exhibiting a robust CAGR of 9.2% during the forecast period. This growth underscores the increasing significance of contract development and manufacturing organizations (CDMOs) and contract research and development organizations (CRDMOs) in accelerating drug discovery, therapeutic oligonucleotide production, and diagnostic innovation. With the rise of precision medicine and advanced biotech therapies, the demand for specialized oligonucleotide manufacturing and research services has surged globally.
Explore Key Insights in the Free Sample https://www.24lifesciences.com/download-sample/5181/oligonucleotide-cdmo-and-crdmo-services-market-market
Market Highlights
Segment Analysis
By Type:
- Research Grade Oligonucleotides – Widely used for laboratory research and early-stage development.
- GMP Grade Oligonucleotides – Key for clinical and commercial applications, driving market growth due to regulatory compliance and quality assurance.
By Application:
- Therapeutic Development – Leading segment, propelled by the rise in antisense, siRNA, and gene therapy applications.
- Diagnostic Applications – Growth fueled by precision diagnostics and biomarker development.
- Research and Development – Supports academic and pharmaceutical innovation.
- Others – Includes agricultural and industrial research applications.
By End User:
- Pharmaceutical and Biotechnology Companies – Primary consumers, leveraging CDMO/CRDMO services to streamline drug development.
- Academic and Research Institutions – Increasingly adopting oligonucleotide solutions for translational research.
- Contract Research Organizations – Collaborate with CDMOs/CRDMOs to enhance service offerings.
Explore Key Insights in the Free Sample https://www.24lifesciences.com/download-sample/5181/oligonucleotide-cdmo-and-crdmo-services-market-market
Emerging Trends Shaping the Oligonucleotide Services Market
The integration of AI and machine learning in oligonucleotide design, high-throughput sequencing, and automation in synthesis and purification are transforming market dynamics. Additionally, digital health platforms and bioinformatics-driven research enable faster discovery of novel therapeutic targets. Sustainability in biopharmaceutical manufacturing is also gaining traction, with CDMOs focusing on greener synthesis processes and reducing operational carbon footprints. These innovations are expected to accelerate growth and enhance market efficiency through 2032.
Regional Analysis
- North America: Dominates the market due to well-established pharmaceutical infrastructure, presence of leading CDMOs, and government support for biotech research.
- Europe: Significant growth driven by investments in GMP-grade oligonucleotide manufacturing and R&D initiatives in Germany, Switzerland, and the U.K.
- Asia-Pacific: Fastest-growing region due to emerging biotech hubs in South Korea, Japan, and China, coupled with cost-efficient manufacturing capabilities.
- Rest of the World: Expanding adoption in Latin America and the Middle East is supported by increasing research collaborations and healthcare modernization programs
Key Players & Competitive Landscape
The market features highly competitive dynamics, with key players focusing on capacity expansion, strategic partnerships, and new product development. Notable companies include:
- Lonza Group (Switzerland) – Market leader with robust CDMO capabilities and global presence.
- Thermo Fisher Scientific Inc. (USA) – Offers integrated solutions across oligonucleotide R&D and production.
- Samsung Biologics (South Korea) – Expanding into oligonucleotide manufacturing with advanced GMP facilities.
- Charles River Laboratories (USA) – Specializes in preclinical and early-stage development services.
- Catalent, Inc. (USA) – Provides comprehensive oligonucleotide CDMO services including clinical-scale GMP manufacturing.
- Fujifilm Holdings Corporation (Japan) – Focused on oligonucleotide synthesis and GMP-grade production.
- CordenPharma International GmbH (Germany) – Offers high-quality oligonucleotide manufacturing and purification services.
- Ajinomoto Bio-Pharma Services (USA) – Emphasizes biopharmaceutical and oligonucleotide development services.
These companies are actively pursuing M&A activities, collaborations with academic institutions, and expansion of GMP manufacturing capabilities to meet growing global demand.
Growth Outlook
With the global oligonucleotide CDMO and CRDMO services market projected to reach USD 2.62 billion by 2031, stakeholders are encouraged to invest in innovative manufacturing platforms, AI-driven oligonucleotide design, and strategic collaborations. Increasing adoption of gene therapy, antisense, and RNA-based therapeutics will continue to fuel market expansion, while advancements in regulatory frameworks and precision medicine further strengthen growth prospects.
Gain Full Market Insights – Access the Complete Report https://www.24lifesciences.com/oligonucleotide-cdmo-and-crdmo-services-market-market-5181
Explore our related reports
About 24lifesciences
Founded in 2017, 24LifeScience has emerged as a trusted research and analytics partner for organizations operating within the global life sciences and chemical industries. Our core mission is to provide intelligent, future-ready insights that help clients stay ahead in an increasingly complex and innovation-driven market
International: +1(332) 2424 294 | Asia: +91 9425150513 (Asia)
Website: www.24lifesciences.com
Follow us on LinkedIn: www.linkedin.com/company/lifesciences24
- Single-Domain Heavy Chain Antibody Market - 2026-01-23
- Qianlie Antong Capsules Market - 2026-01-23
- Veterinary Amitraz Solution Market - 2026-01-23